Portola Pharmaceuticals Inc. may need a randomized trial for US approval of its AndexXa (andexanet alfa) antidote for Factor Xa anticoagulants, raising concerns that this would be needed prior to approval, delaying launch by years.
The company disclosed FDA's potential request during its earnings call on Wednesday, Feb